Clinical trial
The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of…
NCT00464737 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00464737 |
|---|---|
| Title | The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. |
| Official title | A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Doses of Rotigotine in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome |
| Acronym | SP888 |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fibromyalgia Syndrome |
| Intervention type | Drug, Other |
| Interventions | Rotigotine, Placebo |
| Enrollment | 230 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Apr 24, 2007 |
| Last update posted | Jun 22, 2015 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: